title: Cytomegalovirus peritonitis after renal transplantation under induction therapy with alemtuzumab in a young woman previously treated with peritoneal dialysis.
authors.forename: Matthias
authors.initials: M
authors.lastname: Meier
authors.forename: Markus
authors.initials: M
authors.lastname: Hiss
authors.forename: Carsten
authors.initials: C
authors.lastname: Hafer
authors.forename: Werner
authors.initials: W
authors.lastname: Buth
authors.forename: Joerg
authors.initials: J
authors.lastname: Radermacher
authors.forename: Hermann
authors.initials: H
authors.lastname: Haller
authors.forename: Anke
authors.initials: A
authors.lastname: Schwarz
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000472:pathogenicity; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D010530:Peritoneal Dialysis; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab